|

Vibegron Clinical Trials

1 actively recruiting trial across 1 location

No change since June 2026

Pipeline

Phase 2/3: 1

Top Sponsors

  • Urovant Sciences GmbH1

Indications

  • Neurogenic Detrusor Overactivity1
  • Cancer1

Little Rock, Arkansas1 trial

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

Arkansas Childrens Hospital

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.